ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "giant cell arteritis"

  • Abstract Number: 1395 • ACR Convergence 2021

    Utility and Validity of the Southend Pretest Probability Score (SPTPS) in a Giant Cell Arteritis Fast Track Clinic: Analysis in a Spanish Cohort of 297 Patients

    Elisa Fernández-Fernández1, Irene Monjo2 and Eugenio De Miguel3, 1Rheumatology department, La Paz University Hospital, Madrid, Spain, 2Hospital La Paz - IdiPAZ, Madrid, Spain, 3Hospital Universitario La Paz, Madrid, Spain

    Background/Purpose: The implementation of fast track clinics (FTC) has enabled quick diagnosis and reduced the blindness rate of giant cell arteritis (GCA). Recently, the Southend…
  • Abstract Number: 1412 • ACR Convergence 2021

    Effectiveness of Tocilizumab in the Visual Involvement of Giant Cell Arteritis: Multicenter Study of 471 Patients of Clinical Practice

    Lara Sánchez-Bilbao1, Javier Loricera1, Juan Pablo Valdivieso Achá2, Clara Moriano3, Javier Narvaez4, Vicente Aldasoro5, Olga Maíz6, Rafael Melero7, Juan Ignacio Villa8, Paloma Vela9, Susana Romero-Yuste10, José Luis Callejas11, Eugenio De Miguel12, Eva Galindez-Agirregoikoa13, Francisca Sivera14, Jesús Carlos Fernández-López15, Carles Galisteo16, Iván Ferraz-Amaro17, Juan Carlos Nieto18, Juan Ramón de Dios19, Julio Sánchez20, Esther Fernández21, Isabel de la Morena22, Patricia Moya23, Roser Solans-Laqué24, Jose Luis Andreu25, Marcelino Revenga26, Valvanera Pinillos27, Andrea García-Valle28, Adela Gallego29, Carlota Iñíguez30, Cristina Hidalgo31, Noemí Garrido-Puñal32, Ruth López-González33, José Andrés Román-Ivorra34, Sara Manrique Arija35, Paz Collado36, Enrique Raya11, Francisco Navarro37, Antoni Juan Mas38, Carmen Ordas39, Maria Dolors Boquet40, Noelia Álvarez-Rivas41, Maria Luisa Velloso-Feijoo42, Cristina Campos-Fernández43, Íñigo Rúa-Figueroa44, Arantxa Conesa45, Eva Salgado46, Miguel Ángel gonzalez-Gay47 and Ricardo Blanco48, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario La Princesa, Madrid, Spain, 3Hospital Universitario de León, León, Spain, 4Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 5Complejo Hospitalario de Navarra, Pamplona, Spain, 6Hospital Universitario de Donostia, San Sebastián, Spain, 7Complexo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, 8Hospital Sierrallana, Torrelavega, Spain, 9Hospital General Universitario de Alicante, Alicante, Spain, 10Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, 11Hospital San Cecilio, Granada, Spain, 12Hospital Universitario La Paz, Madrid, Spain, 13Hospital Universitario de Basurto, Bilbao, Spain, 14Hospital Universitario de Elda, Alicante, Spain, 15Hospital Universitario Juan Canalejo, A Coruña, Spain, 16Hospital Universitari Parc Tauli, Saadell, Spain, 17Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 18Hospital General Universitario Gregorio Marañón, Madrid, Spain, 19Hospital Universitario de Araba, Mondragón, Spain, 20Hospital Universitario 12 de Octubre, Madrid, Spain, 21Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, 22Hospital Clínico Universitario de Valencia, Valencia, Spain, 23Hospital Sant Pau, Barcelona, Spain, 24Hospital Vall d'Hebron, Barcelona, Spain, 25Hospital Universitario Puerta de Hierro, Madrid, Spain, 26Hospital Ramón y Cajal, Madrid. Spain., Madrid, Spain, 27Hospital San Pedro, Logroño, Spain, 28Complejo Asistencial Universitario de Palencia, Palencia. Spain, Palencia, Spain, 29Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, 30Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain, 31Hospital Universitario Salamanca, Salamanca, Spain, 32Hospital Universitario Virgen del Rocío, Sevilla, Spain, 33Complejo Hospitalario de Zamora, Zamora, Spain, 34Hospital Universitario y Politécnico La Fe, Valencia, Spain, 35Hospital Regional de Málaga, Málaga. Spain., Malaga, Spain, 36Hospital Universitario Severo Ochoa, Madrid, Spain, 37Hospital General Universitario de Elche, Elche, Spain, 38Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, 39Hospital de Cabueñes, Gijón, Spain, 40Hospital Arnau de Vilanova, Lleida. Spain., Lleida, Spain, 41Hospital San Agustín, Aviles, Spain, 42Hospital Universitario de Valme, Sevilla, Spain, 43Consorci Hospital General Universitari de Valencia, Valencia, Spain, 44Hospital Universitario Doctor Negrín, Gran Canaria, Spain, 45Hospital Universitario de Castellón, Castellón, Spain, 46Complejo Hospitalario Universitario de Ourense, Ourense, Spain, 47Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 48Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: One of the most feared complications of giant cell arteritis (GCA) is visual affection. Tocilizumab (TCZ) has demonstrated efficacy and safety in GCA. However,…
  • Abstract Number: 1396 • ACR Convergence 2021

    Baricitinib in Relapsing Giant Cell Arteritis: A Prospective Open-Label Single-Institution Study

    Matthew Koster1, Cynthia Crowson2, Rachel Giblon1, Ali Duarte-Garcia1, Jane Jaquith1, Cornelia M. Weyand1 and Kenneth Warrington3, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Eyota, MN, 3Mayo Clinic, Rochester, Minnesota

    Background/Purpose: Pre-clinical giant cell arteritis (GCA) mouse models have demonstrated effective suppression of arterial wall lesional T-cells through inhibition of Janus kinase 3 (JAK3) and…
  • Abstract Number: 1413 • ACR Convergence 2021

    Tocilizumab in Combination with 8 Weeks of Prednisone for Giant Cell Arteritis

    Mark Matza1, Adam Jarvie2, Ana Fernandes1, John Stone3 and Sebastian Unizony4, 1Massachusetts General Hospital, Boston, MA, 2Masssachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 4Massachusetts General Hospital, Winchester, MA

    Background/Purpose: Even with the use of tocilizumab (TCZ), significant glucocorticoid exposure (usually ³ 6 months) continues to be an important problem in giant cell arteritis…
  • Abstract Number: 1397 • ACR Convergence 2021

    Treatment of Giant Cell Arteritis with Tocilizumab: A Retrospective Cohort Study of 119 Patients

    jigisha rakholiya1, Matthew Koster1, Hannah Langenfeld1, Cynthia Crowson2, Andy Abril3, Pankaj Bansal4, Lester Mertz5, Alicia Rodriguez Pla6, Rahul Sehgal4, Benjamin Wang7 and Kenneth Warrington8, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Eyota, MN, 3Mayo Clinic, Ponte Vedra Beach, FL, 4Mayo Clinic, Eau Claire, WI, 5Mayo Clinic Arizona, Scottsdale, AZ, 6Mayo Clinic in Arizona, Scottsdale, AZ, 7Mayo Clinic, Jacksonville, FL, 8Mayo Clinic, Rochester, Minnesota

    Background/Purpose: Giant cell arteritis (GCA) is an inflammatory condition of medium- and large-sized arteries. Prospective clinical trials have demonstrated the efficacy of tocilizumab (TCZ) for…
  • Abstract Number: 1414 • ACR Convergence 2021

    The Current State of Expedited Referral Systems Incorporating Vasculitis Ultrasound for the Diagnosis of Giant Cell Arteritis in Rheumatology Practices in the United States

    Mark Matza1, Karina Torralba2 and Minna Kohler3, 1Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA, 3Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Expedited referral systems or “fast-track” clinics incorporating vasculitis ultrasound (VUS) into the evaluation of patients with suspected giant cell arteritis (GCA) have shown reduced…
  • Abstract Number: 1398 • ACR Convergence 2021

    Adrenal Insufficiency After Glucocorticoid Treatment of Giant Cell Arteritis

    Alojzija Hocevar1, Rok Jese1, Jelka Kramaric2, Matija Tomšič3 and Ziga Rotar3, 1UKC Ljubjana, Ljubjana, Slovenia, 2UKC Ljubjana, Ljubjana, 3Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia

    Background/Purpose: Adrenal insufficiency is frequently neglected and underappreciated complication of systemic glucocorticoid therapy. We aimed to evaluate the prevalence of glucocorticoid induced adrenal insufficiency in…
  • Abstract Number: 1415 • ACR Convergence 2021

    Temporal Artery Biopsy Reports Can Be Accurately Classified by Artificial Intelligence

    Christopher McMaster1, Victor Yang1, Benjamin Sutu2, Shereen Oon3, Gene-Siew Ngian3, Ian Wicks3, Russell Buchanan4 and David Liew1, 1Austin Health, Heidelberg, Australia, 2Melbourne Health, South Yarra, Australia, 3Melbourne Health, Parkville, Australia, 4Austin Health, Heidelberg, Melbourne, Australia

    Background/Purpose: Studies of giant cell arteritis (GCA) rely on classifying temporal artery biopsies (TABs), the gold-standard diagnostic test. However, these results exist as free text,…
  • Abstract Number: 0151 • ACR Convergence 2021

    Usefulness of Ultrasound and (FDG) PET/CT to Detect Cranial and Extracranial Artery Involvement in Patients with Suspected Large Vessel Vasculitis

    Juan Molina1, Isabel Castrejón2, Javier Rivera2, Julia Martínez Barrio2, Juan Carlos Nieto2, Katerine López2, Fernando Montero2, Laura Trives Folguera2, Carlos González3 and Jose Maria Alvaro-Gracia2, 1Hospital General Universitario Gregorio Maran, Madrid, Spain, 2Hospital General Universitario Gregorio Marañón, Madrid, Spain, 3CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    Background/Purpose: Ultrasound (US) is recommended as the first imaging modality to assess patients presenting with predominantly cranial symptoms of giant cell arteritis (GCA). However, its…
  • Abstract Number: 1399 • ACR Convergence 2021

    Validation of a Giant Cell Arteritis Probability Score

    Charlie Oshinsky1, Alison Bays1, Ingeborg Sacksen2, Elizabeth Jernberg3, Eugene zierler1, Andreas Diamantopoulos4 and Scott Pollock1, 1University of Washington, Seattle, WA, 2University of Washington, Bellingham, WA, 3Virginia Mason Medical Center, Seattle, WA, 4Akerhus University Hospital, Brum, Norway

    Background/Purpose: Giant cell arteritis (GCA) is the most common large vessel vasculitis. Failure to rapidly diagnose and treat patients with GCA can result in irreversible…
  • Abstract Number: 1416 • ACR Convergence 2021

    Dysregulated Glucose Metabolism and Dyslipidemia in GCA and PMR Patients at Diagnosis

    Idil Esen1, Philip Therkildsen2, Berit Dalsgaard Nielsen2, Anna van 't Ende1, Annemieke Boots1, Peter Heeringa1, Ellen-Margrethe Hauge2, Elisabeth Brouwer1 and Yannick van Sleen3, 1University Medical Center Groningen, Groningen, Netherlands, 2Aarhus University Hospital, Aarhus, Denmark, 3University of Groningen, Groningen, Netherlands

    Background/Purpose: Giant cell arteritis (GCA) is the large and medium vasculitis that affects elderly people GCA frequently overlaps with polymyalgia rheumatica (PMR). PMR is a…
  • Abstract Number: 0163 • ACR Convergence 2021

    Diagnosis of Giant Cell Arteritis in Spain: Data from the ARTESER Registry

    Eugenio De Miguel1, Jesús T. Sánchez-Costa2, Javier Narvaez3, Miguel Ángel gonzalez-Gay4, Noemí Garrido-Puñal5, Paula V. Estrada-Alarcon6, Iñigo Hernández-Rodríguez7, Elisa Fernández-Fernández8, María T. Silva-Diaz9, Jesús A. Valero-Jaimes10, Ismael González-Fernández11, Julio Sánchez12, Judit Lluch13, Eva Galindez-Agirregoikoa14, Javier Mendizábal-Mateos15, Luis Rodriguez Rodriguez16, Javier Loricera García17, Alejandro Muñoz18, Santos Castañeda19, Patricia Moya20, Patricia Morán-Álvarez21, Vanessa A. Navarro-Angeles6, Joan Calvet-Fontova22, Ivette Casafont23, Francisco Ortiz-Sanjuán24, Selene Labrada-Arrabal25, Cristina Campos-Fernández26, María Alcalde-Villar27, Antonio Juan-Mas28 and Ricardo Blanco29, 1Hospital Universitario La Paz, Madrid, Spain, 2Spanish Society of Rheumatology, Madrid, Spain, 3Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 4Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5Hospital Universitario Virgen del Rocío, Sevilla, Spain, 6Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, 7Complejo Hospitalario Universitario de Vigo, Vigo, Spain, 8Rheumatology department, La Paz University Hospital, Madrid, Spain, 9Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, 10Hospital Universitario Donostia, Donostia-San Sebasti, Spain, 11Hospital Universitario de León, León, Spain, 12Hospital Universitario 12 de Octubre, Madrid, Spain, 13Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, 14Hospital Universitario de Basurto, Bilbao, Spain, 15H. Navarra, Navarra, Spain, 16Hospital Clinico San Carlos, Madrid, Spain, 17Hospital Universitario Marqués de Valdecilla, Santander, Spain, 18Hospital Universitario Virgen del Rocío, Sevial, Spain, 19Hospital Universitario de la Princesa, Madrid, Spain, 20Hospital Sant Pau, Barcelona, Spain, 21Hospital Universitario Ramón y Cajal, Madrid, Spain, 22Hospital Universitari Parc Tauli, Sabadell, Spain, 23Hospital Universitari Germans Trias i Pujol, Barcelona, Badalona, Spain, 24H. La Fe, Valencia, Spain, 25Hospital del Mar, Barcelona, Spain, 26Consorci Hospital General Universitari de Valencia, Valencia, Spain, 27Hospital Universitario Severo Ochoa, Leganés, Spain, 28Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, 29Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: To standardize research studies different classification systems are used. Currently, the ACR Giant Cell Arteritis (GCA) 19901 classification criteria is probably the most widely…
  • Abstract Number: 1400 • ACR Convergence 2021

    Analyses of Plasma Inflammatory Proteins Reveal Biomarkers Predictive of Subsequent Development of Giant Cell Arteritis; A Nested Case-Control Study

    Karin Wadström1, Jan-Åke Nilsson1, Aladdin Mohammad2, Kenneth Warrington3, Eric Matteson4, Magnus Jakobsson2, Lennart Jacobsson5 and Carl Turesson6, 1Lund University, Malmö, Sweden, 2Lund University, Lund, Sweden, 3Mayo Clinic, Rochester, MN, 4Mayo Clinic College of Medicine and Science, Rochester, MN, 5University of Gothenburg, Gothenburg, Sweden, 6Lund University, Malm, Sweden

    Background/Purpose: Previous studies have demonstrated that metabolic factors may predispose to giant cell arteritis (GCA). The purpose of this study was to investigate the relation…
  • Abstract Number: 1417 • ACR Convergence 2021

    Machine Learning Enhances the Identification of GCA from Its Mimics Based on Clinical Factors

    Christopher McMaster1, Victor Yang1, Russell Buchanan2 and David Liew1, 1Austin Health, Heidelberg, Australia, 2Austin Health, Heidelberg, Melbourne, Australia

    Background/Purpose: To determine whether an eventual diagnosis of giant cell arteritis in both temporal artery biopsy positive and negative patients can be identified using prospective…
  • Abstract Number: 0466 • ACR Convergence 2021

    Subclinical Large Vessel Vasculitis in Polymyalgia Rheumatica

    Eugenio De Miguel1, Pierluigi Macchioni2, Edoardo Conticini3, Corrado Campochiaro4, Rositsa Karalilova5, Giulia Klinowski2, Paolo Falsetti3, Irene Monjo6, Alessandro Tomelleri7, Zguro Batalov5 and Alojzija Hocevar8, 1Hospital Universitario La Paz, Madrid, Spain, 2Department of Rheumatology, IRCCS-S.Maria Nuova, Reggio Emilia, Italy, 3Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy, 4Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR). San Raffaele Scientific Institute, Milan. Italy, Milan, Italy, 5Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, 6Hospital La Paz - IdiPAZ, Madrid, Spain, 7Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR). San Raffaele Scientific Institute, Milan, Milan, Italy, 8UKC Ljubjana, Ljubjana, Slovenia

    Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related diseases. PMR occurs in approximately 50 % of GCA patients1, however the frequency…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 32
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology